Atyr PHARMA (NASDAQ:ATYR) Now Covered by Leerink Partners

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a report released on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $16.00 price objective on the stock.

ATYR has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Trading Up 4.4 %

NASDAQ:ATYR opened at $4.44 on Tuesday. The stock has a fifty day moving average price of $3.58 and a 200 day moving average price of $2.86. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.57. The firm has a market cap of $372.27 million, a PE ratio of -4.72 and a beta of 1.10.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATYR. JPMorgan Chase & Co. raised its position in shares of Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after acquiring an additional 10,754 shares in the last quarter. Alterna Wealth Management Inc. purchased a new position in Atyr PHARMA in the fourth quarter valued at approximately $36,000. Kingswood Wealth Advisors LLC purchased a new position in Atyr PHARMA in the fourth quarter valued at approximately $170,000. American Century Companies Inc. acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $319,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Atyr PHARMA during the 4th quarter worth approximately $39,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.